In the PPI network, we identified 10 key genes, namely AKT1, MYC, CASP3, ESR1, EGFR, HIF-1A, VEGFA, JUN, INS, and STAT3, which may be the core targets of BZD therapy for CRC. This evidence concerns the gene MYC and colorectal carcinoma.